Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk (JMAS.JK)
Jakarta Selatan, ID
PT Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk is an Indonesian firm specializing in sharia-compliant life insurance. The company's comprehensive portfolio encompasses various offerings, including individual and group life and health policies, term coverage, combined dual-purpose plans, dedicated sharia life products, personal protection, and financing insurance solutions. Established in 2014, its principal office is situated in Jakarta Selatan, Indonesia. This entity functions as a subsidiary of Kospin Jasa.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.02% | +2.92% | +21.55% | +22.61% | +84.31% | +27.03% | +108.89% | +347.62% | +77.36% | +18.49% | +18.49% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Insurance - Life: +10.6%+9.4% Q3'25: +144.5% (vs Q3'24)
-
EPS growth Insurance - Life: +13.4%+11.9% Q3'25: +75.6% (vs Q3'24)
-
FCF margin FCF growth · Insurance - Life: +31.7%+3.6% Q3'25: -37.5% (vs Q3'24)
-
EBIT margin Insurance - Life: +12.4%+4.8% Q3'25: +3.9% (vs Q3'24)
-
ROIC Insurance - Life: +1.0%+2.3% ★ Q3'25: +7.0% (vs Q3'24)
-
Share dilution Insurance - Life: +0.4%+0.0% Q3'25: +0.0% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Insurance - Life: -1.05×0.00× Q3'25: 0.00× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aji Darmaji | Director of Operations & Director | — | male |
| Ari Setiawan | Information & Technology Manager | — | — |
| Basuki Agus | President Director | — | male |
| Gus Imron | Marketing Director & Director | — | male |
| Hery Al Hariry | Company Actuary & Head of Actuarial Division | — | male |
| Mawar Arsiani Djunaid | Deputy President Director & Corporate Secretary | — | — |
| Saroyo | Head of Finance Division | — | — |
| Setyo Utomo | Head of Internal Audit Unit | — | male |
| Sonny Widiyasana | Head of Technical Division | — | — |
| Suwanto | Head of Marketing Retail Division | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JMAS.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
